Literature DB >> 22830633

Counting the cost of not costing HIV health facilities accurately: pay now, or pay more later.

Eduard J Beck1, Carlos Avila, Sofia Gerbase, Guy Harling, Paul De Lay.   

Abstract

The HIV pandemic continues to be one of our greatest contemporary public health threats. Policy makers in many middle- and low-income countries are in the process of scaling up HIV prevention, treatment and care services in the context of a reduction in international HIV funding due to the global economic downturn. In order to scale up services that are sustainable in the long term, policy makers and implementers need to have access to robust and contemporary strategic information, including financial information on expenditure and cost, in order to be able to plan, implement, monitor and evaluate HIV services. A major problem in middle- and low-income countries continues to be a lack of basic information on the use of services, their cost, outcome and impact, while those few costing studies that have been performed were often not done in a standardized fashion. Some researchers handle this by transposing information from one country to another, developing mathematical or statistical models that rest on assumptions or information that may not be applicable, or using top-down costing methods that only provide global financial costs rather than using bottom-up ingredients-based costing. While these methods provide answers in the short term, countries should develop systematic data collection systems to store, transfer and produce robust and contemporary strategic financial information for stakeholders at local, sub-national and national levels. National aggregated information should act as the main source of financial data for international donors, agencies or other organizations involved with the global HIV response. This paper describes the financial information required by policy makers and other stakeholders to enable them to make evidence-informed decisions and reviews the quantity and quality of the financial information available, as indicated by cost studies published between 1981 and 2008. Among the lessons learned from reviewing these studies, a need was identified for providing countries with practical guidance to produce reliable and standardized costing data to monitor performance, as countries want to improve programmes and services, and have to demonstrate an efficient use of resources. Finally, the issues raised in this paper relate to the provision of all areas of healthcare in countries and it is going to be increasingly important to leverage the lessons learned from the HIV experience and use resources more effectively and efficiently to improve health systems in general.

Mesh:

Year:  2012        PMID: 22830633     DOI: 10.2165/11596500-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  22 in total

Review 1.  The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008.

Authors:  Eduard J Beck; Guy Harling; Sofia Gerbase; Paul DeLay
Journal:  Curr Opin HIV AIDS       Date:  2010-05       Impact factor: 4.283

2.  Cost-effectiveness analysis: can we reduce variability in costing methods?

Authors:  Taghreed Adam; Marc A Koopmanschap; David B Evans
Journal:  Int J Technol Assess Health Care       Date:  2003       Impact factor: 2.188

3.  Combination prevention: a deeper understanding of effective HIV prevention.

Authors:  Catherine A Hankins; Barbara O de Zalduondo
Journal:  AIDS       Date:  2010-10       Impact factor: 4.177

4.  Rationing antiretroviral therapy in Africa--treating too few, too late.

Authors:  Nathan Ford; Edward Mills; Alexandra Calmy
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

5.  Financing the response to HIV in low-income and middle-income countries.

Authors:  José Antonio Izazola-Licea; Jan Wiegelmann; Christian Arán; Teresa Guthrie; Paul De Lay; Carlos Avila-Figueroa
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

6.  Viewpoint: a pragmatic approach to constructing a minimum data set for care of patients with HIV in developing countries.

Authors:  William M Tierney; Eduard J Beck; Reed M Gardner; Beverly Musick; Mark Shields; Naomi M Shiyonga; Mark H Spohr
Journal:  J Am Med Inform Assoc       Date:  2006-02-24       Impact factor: 4.497

7.  The distinction between cost and charges.

Authors:  S A Finkler
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

Review 8.  The cost of HIV treatment and care. A global review.

Authors:  E J Beck; A H Miners; K Tolley
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

9.  What is the cost of getting the price wrong?

Authors:  E J Beck; J Beecham; S Mandalia; R Griffith; M D Walters; M Boulton; D L Miller
Journal:  J Public Health Med       Date:  1999-09

10.  Rising population cost for treating people living with HIV in the UK, 1997-2013.

Authors:  Sundhiya Mandalia; Roshni Mandalia; Gary Lo; Tim Chadborn; Peter Sharott; Mike Youle; Jane Anderson; Guy Baily; Ray Brettle; Martin Fisher; Mark Gompels; George Kinghorn; Margaret Johnson; Brendan McCarron; Anton Pozniak; Alan Tang; John Walsh; David White; Ian Williams; Brian Gazzard; Eduard J Beck
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

View more
  10 in total

1.  Resource utilisation and cost of ambulatory HIV care in a regional HIV centre in Ireland: a micro-costing study.

Authors:  Aline Brennan; Arthur Jackson; Mary Horgan; Colm J Bergin; John P Browne
Journal:  BMC Health Serv Res       Date:  2015-04-03       Impact factor: 2.655

2.  Pentacycloundecane lactam vs lactone norstatine type protease HIV inhibitors: binding energy calculations and DFT study.

Authors:  Bahareh Honarparvar; Sachin A Pawar; Cláudio Nahum Alves; Jerônimo Lameira; Glenn Em Maguire; José Rogério A Silva; Thavendran Govender; Hendrik G Kruger
Journal:  J Biomed Sci       Date:  2015-02-18       Impact factor: 8.410

3.  Towards a comprehensive global approach to prevention and control of NCDs.

Authors:  Martin McKee; Andy Haines; Shah Ebrahim; Peter Lamptey; Mauricio L Barreto; Don Matheson; Helen L Walls; Sunia Foliaki; J Jaime Miranda; Oyun Chimeddamba; Luis Garcia-Marcos; Paolo Vineis; Neil Pearce
Journal:  Global Health       Date:  2014-10-28       Impact factor: 4.185

4.  Protecting the confidentiality and security of personal health information in low- and middle-income countries in the era of SDGs and Big Data.

Authors:  Eduard J Beck; Wayne Gill; Paul R De Lay
Journal:  Glob Health Action       Date:  2016-11-23       Impact factor: 2.640

5.  Costs of facility-based HIV testing in Malawi, Zambia and Zimbabwe.

Authors:  Lawrence Mwenge; Linda Sande; Collin Mangenah; Nurilign Ahmed; Sarah Kanema; Marc d'Elbée; Euphemia Sibanda; Thokozani Kalua; Gertrude Ncube; Cheryl C Johnson; Karin Hatzold; Frances M Cowan; Elizabeth L Corbett; Helen Ayles; Hendramoorthy Maheswaran; Fern Terris-Prestholt
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

6.  Assessing the cost of providing a prevention of mother-to-child transmission of HIV/AIDS service in Ethiopia: urban-rural health facilities setting.

Authors:  Elias Asfaw Zegeye; Josue Mbonigaba; Sylvia Kaye; Benjamin Johns
Journal:  BMC Health Serv Res       Date:  2019-03-06       Impact factor: 2.655

7.  The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case.

Authors:  Gesine Meyer-Rath; Craig van Rensburg; Calvin Chiu; Rahma Leuner; Lise Jamieson; Steve Cohen
Journal:  PLoS One       Date:  2019-02-26       Impact factor: 3.240

8.  North-South Corridor Demonstration Project: Ethical and Logistical Challenges in the Design of a Demonstration Study of Early Antiretroviral Treatment for Long Distance Truck Drivers along a Transport Corridor through South Africa, Zimbabwe, and Zambia.

Authors:  G B Gomez; W D F Venter; J M A Lange; H Rees; C Hankins
Journal:  Adv Prev Med       Date:  2013-03-31

9.  Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.

Authors:  Eduard J Beck; Sundhiya Mandalia; Roshni Sangha; Mike Youle; Ray Brettle; Mark Gompels; Margaret Johnson; Anton Pozniak; Achim Schwenk; Stephen Taylor; John Walsh; Ed Wilkins; Ian Williams; Brian Gazzard
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

10.  Econometric estimation of WHO-CHOICE country-specific costs for inpatient and outpatient health service delivery.

Authors:  Karin Stenberg; Jeremy A Lauer; Georgios Gkountouras; Christopher Fitzpatrick; Anderson Stanciole
Journal:  Cost Eff Resour Alloc       Date:  2018-03-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.